Xiaojuan You, Mingyi Shao, Huadong Wang, Rui Zhu, Xinwei Liu, Lei Dong, Yuesheng Gong, Yongwei Li
{"title":"An electrochemical aptasensor for detection of <i>Helicobacter pylori</i> based on AuNPs and AgNPs-GO nanoparticles.","authors":"Xiaojuan You, Mingyi Shao, Huadong Wang, Rui Zhu, Xinwei Liu, Lei Dong, Yuesheng Gong, Yongwei Li","doi":"10.3389/fbioe.2025.1619336","DOIUrl":null,"url":null,"abstract":"<p><p>Helicobacter pylori is one of the main causes of gastritis and gastric ulcer. Early detection of <i>H. pylori</i> is of great significance for the prevention of gastric cancer. Herein, a sensitive electrochemical aptasensor using AgNPs-GO as redox probes was established for the specific detection of <i>H. pylori</i> in blood serum and stool samples. Firstly, AgNPs-GO nanocomposites were obtained by <i>in-situ</i> reduction of AgNPs on graphene oxide (GO) surface with glucose as reducing agent, in which AgNPs showed good biocompatibility and chemical stability, as well as redox property, and GO provided a large surface area to assemble a large number of AgNPs. Subsequently, the electrodeposition of AuNPs further improved the conductivity of the aptasensor. Additionally, the streptavidin was introduced into the aptasensor to effectively bind the biotin-modified aptamers. In this way, aptamers could be tethered to the surface through SA-biotin linkage, and <i>H. pylori</i> was selectivly binded by the aptamers subsequently. Under optimal conditions, the aptasensor could detect <i>H. pylori</i> in a wide concentration range (10<sup>1</sup> CFU mL<sup>-1</sup>-10<sup>8</sup> CFU mL<sup>-1</sup>) with a low detection limit of 3 CFU mL<sup>-1</sup>. What's more, the developed method showed excellent performance in practical application, which provided a promising possibility for the detection of other pathogens in clinical diagnosis.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1619336"},"PeriodicalIF":4.3000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283743/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1619336","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Helicobacter pylori is one of the main causes of gastritis and gastric ulcer. Early detection of H. pylori is of great significance for the prevention of gastric cancer. Herein, a sensitive electrochemical aptasensor using AgNPs-GO as redox probes was established for the specific detection of H. pylori in blood serum and stool samples. Firstly, AgNPs-GO nanocomposites were obtained by in-situ reduction of AgNPs on graphene oxide (GO) surface with glucose as reducing agent, in which AgNPs showed good biocompatibility and chemical stability, as well as redox property, and GO provided a large surface area to assemble a large number of AgNPs. Subsequently, the electrodeposition of AuNPs further improved the conductivity of the aptasensor. Additionally, the streptavidin was introduced into the aptasensor to effectively bind the biotin-modified aptamers. In this way, aptamers could be tethered to the surface through SA-biotin linkage, and H. pylori was selectivly binded by the aptamers subsequently. Under optimal conditions, the aptasensor could detect H. pylori in a wide concentration range (101 CFU mL-1-108 CFU mL-1) with a low detection limit of 3 CFU mL-1. What's more, the developed method showed excellent performance in practical application, which provided a promising possibility for the detection of other pathogens in clinical diagnosis.
期刊介绍：
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
